Table 3.
Early studies of Immunotherapy and chemotherapy in metastatic triple negative breast cancer
|
Trial
|
n
|
Drug
|
ORR 1st line
|
ORR ≥ 2 line
|
mOS 1st line
|
mOS 2nd line
|
Ref.
|
| NCT01633970 Phase Ib | 33 | Atezolizumab + nab-paclitaxel | 53.8% | 30 | 24.2 | 12.4 | Adams et al[55], 2019 |
| KEYNOTE-150 Phase 1b/II | 82 | Pembrolizumab + Eribulin | 25% | 26.5 | 17.7 | NE | Tolaney et al[57], 2018 |
| Pilot and phase II. 1-2L1 | 29 | Pembrolizumab + capecitabine or paclitaxel | 43% pembro + cap. 23% pembro + paclitaxel | 13.8 pembro + cap 7.9 pembro + pac | Page et al[90], 2019 |
1
One to two lines of prior treatment. Pembro: Pembrolizumab; Cap: Capecitabine; Pac: Paclitaxel; ORR: Overall response rate; OS: Overall survival.